A new approach to the preparation of ,'-unsymmetrically substituted 9-aminobispidines through aminal bridge removal reaction has been developed, the principal feature of which is the ability to selectively functionalize all three nitrogen atoms. The intermediates of 1,3-diazaadamantane's aminal bridge removal reaction are characterized, and the mechanism of this reaction is proposed based on the analysis of their structures. Representatives of the previously unknown saturated heterocyclic 1,5,9-triazatricyclo[5.3.1.0]undecane system were obtained and structurally characterized. Thus, it was possible for the first time to obtain 3,7,9-trisubstituted bispidines containing acetyl, Boc, and benzyl groups at nitrogen atoms, which can be independently removed (orthogonal protective groups).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.joc.3c00514 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MRGPRX2 ligandome: Molecular simulations reveal three categories of ligand-receptor interactions.
J Struct Biol
March 2025
Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-University Erlangen-Nürnberg, Germany; Helmholtz Institute for Translational Oncology (HI-TRON Mainz)-a Helmholtz institute by DKFZ, Mainz, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address:
Introduction: Mas-related G protein-coupled receptor (MRGPR) X2 is a mast cell receptor known to be activated by a wide range of ligands of various size, charge and origin. Our aim is to gain a deeper understanding of the binding processes of the different MRGPRX2 ligands and the ligand-receptor interactions in order to identify crucial structural elements for receptor activation.
Materials And Methods: We used the three-dimensional structure of MRGPRX2 described in Nature in 2021 by Cao et al.
Genotoxicity of putrescine and its effects on gene expression in HepG2 cell line.
Toxicol In Vitro
March 2025
Universidade Estadual Paulista "Júlio de Mesquita Filho" - Campus Rio Claro, Instituto de Biociências, Departamento de Biologia Geral e Aplicada, Avenida 24-A, n° 1515, Bela Vista, CEP 13506-900 Rio Claro, São Paulo, Brazil. Electronic address:
Decomposing bodies release necro-leachate, a toxic fluid containing harmful compounds such as biogenic amines. This study investigated the genotoxic effects of the different concentrations (0.5, 1.
View Article and Find Full Text PDFTissue-Adaptable Hydrogel for Mechanically Compliant Bioelectronic Interfaces.
Nano Lett
March 2025
Yunlong Lake Laboratory of Deep Underground Science and Engineering, Xuzhou 221116, China.
A hydrogel with tissue-like softness and ideal biocompatibility has emerged as a promising candidate for bioelectronics, especially in bidirectional bioelectrical transduction and communication. Conformal standardized hydrogel biointerfaces are in urgent demand to bridge electronic devices and irregular tissue surfaces. Herein, we presented a shape-adaptative electroactive hydrogel with tissue-adapted conductivity (≈1.
View Article and Find Full Text PDFPhase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.
Front Immunol
March 2025
State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Introduction: Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effects remains unclear as induction therapy for AML.
View Article and Find Full Text PDFChidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia.
Cancer Med
March 2025
State Key Laboratory of Experimental Hematology, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Introduction: Currently, there are only a few avaailable treatment options for patients with relapsed and refractory acute myeloid leukemia (R/R AML).
Methods: We conducted a single-center, phase 1 prospective study (ChiCTR2200065634) to evaluate the efficacy and safety of chidamide, demethylating drugs (azacitidine), cytarabine, aclacinomycin, and G-CSF plus venetoclax (CDCAG-VEN) in patients with R/R AML. The previous CDCAG regimen was used as a historical control to compare its efficacy and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!